[The results of using high-dose methotrexate in treating osteogenic sarcoma]. / Rezul'taty primeneniia vysokikh doz metotreksata pri lechenii otseogennoi sarkomy.

The interim results of the use of high-dose methotrexate with leucovorin rescue for the treatment of 26 patients with osteogenic sarcoma are discussed. Preoperative chemotherapy was followed by marked regression of primary tumor in one out of seven patients with localized disease. In that group, metastasis-free period lasted 2, 3, 10+, 12, 17+ and 24+ months. Response was observed in two out of 19 (10.6%) cases of metastases. Toxic side-effects were moderate and were mainly nausea (38.5% of patients), vomiting (26.9%), elevation of serum transaminase levels (38.5%) and fever (30.7% of cases).

[The mechanisms of a decrease in the toxic action of cisplatin when administered jointly with preparation K-2-9 to mice with melanoma B16]. / O nekotorykh mekhanizmakh snizheniia toksicheskogo deistviia tsisplatina pri sovmestnom vvedenii s preparatom K-2-9 mysham s melanomoi B-16.

The K-2-9 preparation was determined to change cis-platinum pharmacokinetics, that resulted in its pharmacodynamics alterations. The higher Pt concentrations in the blood of animals which were given the K-2-9 preparation provided selectivity of cytostatic accumulation in the tumour tissue, that was accompanied by more prolonged inhibition of the DNA synthesis. A decrease in the toxicity of cis-platinum is associated with a change in the elimination pathway and acceleration of its removal from the organism.